Satish kumar Yadav,
Manyta Yadav,
Mohd. Wasiullah,
Piyush Yadav,
Priyanshu Upadhyay,
- Associate Professor Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Professor Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Principal Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Academic Head Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
- Research Scholar Department of Pharmacy, Prasad Institute of Technology, Jaunpur Uttar Pradesh India
Abstract
Quantitative Structure-Activity Relationship stands at the forefront of Computer-Aided Drug Design, providing a systematic framework for understanding the relationship between the chemical structure of molecules and their biological activity. The present review delves into the multifaceted realm of quantitative structure-activity relationship methodologies within the landscape of drug discovery. Through an exploration of diverse quantitative structure-activity relationship models, molecular descriptors, validation techniques, and recent advancements, the present article aims to elucidate the pivotal role of quantitative structure-activity relationship in accelerating the development of novel therapeutics. By dissecting the intricacies of quantitative structure-activity relationship analysis and its application in rational drug design, the present review sheds light on the transformative potential of computational modeling in shaping the future of pharmaceutical research. Quantitative structureactivity relationship is a pivotal technique in computer-aided drug design that aids in the rational design of novel drug candidates. The present review provides a comprehensive overview of quantitative structure-activity relationship methodologies, their applications, strengths, limitations, and recent advancements in the field of computer-aided drug design. By exploring various quantitative structureactivity relationship models, datasets, molecular descriptors, and statistical techniques, the present article aims to shed light on the significance of quantitative structure-activity relationship in accelerating drug discovery processes.
Keywords: Receptor, drug designing, biological interaction, molecular docking, modelling, drug discovery, computer-aided drug design, docking, multi-target searching, quantitative structure-activity relationship.
[This article belongs to Research & Reviews: A Journal of Pharmaceutical Science(rrjops)]
References
1. T. Hou and X. Xu, “Recent development and application of virtual screening in drug discovery: an overview,” Current Pharmaceutical Design, vol. 10, no. 9, pp. 1011–1033, 2004.
2. W. Yu and A. D. Mac Kerell, “Computer-aided drug design methods,” in Antibiotics, Humana Press, New York, NY, 2017.
3. S. J. Y. Macalino, V. Gosu, S. Hong, and S. Choi, “Role of computer-aided drug design in modern drug discovery,” Archives of Pharmacal Research, vol. 38, no. 9, pp. 1686– 1701, 2015.
4. H.-J. Huang, H. W. Yu, C.-Y. Chen et al., “Current developments of computer-aided drug design,” Journal of the Taiwan Institute of Chemical Engineers, vol. 41, no. 6, pp. 623–635, 2010.
5. M. Hassan Baig, K. Ahmad, S. Roy et al., “Computer aided drug design: success and limitations,” Current Pharmaceutical Design, vol. 22, no. 5, pp. 572–581, 2016.
6. M. Batool, B. Ahmad, and S. Choi, “A structure-based drug discovery paradigm,” International Journal of Molecular Sciences, vol. 20, no. 11, p. 2783, 2019.
7. S. Kalyaanamoorthy and Y.-P. P. Chen, “Structure-based drug design to augment hit discovery,” Drug Discovery Today, vol. 16, no. 17–18, pp. 831–839, 2011.
8. D. E. Clark, “What has computer-aided molecular design ever done for drug discovery?,” Expert Opinion on Drug Discovery, vol. 1, no. 2, pp. 103–110, 2006.
9. A. C. Anderson, “The process of structure-based drug design,” Chemistry & Biology, vol. 10, no. 9, pp. 787–797, 2003.
10. X. Wang, K. Song, L. Li, and L. Chen, “Structure-based drug design strategies and challenges,” Current Topics in Medicinal Chemistry, vol. 18, no. 12, pp. 998–1006, 2018.
11. V. K. Vyas, R. D. Ukawala, C. Chintha, and M. Ghate, “Homology modeling a fast tool for drug discovery: current perspectives,” Indian Journal of Pharmaceutical Sciences, vol. 74, no. 1, pp. 1–17, 2012.
12. I. M. Kapetanovic, “Computer-aided drug discovery and development (CADDD): in silico-chemico- biological approach,” Chemico-Biological Interactions, vol. 171, no. 2, pp. 165–176, 2008.
13. S. F. Sousa, P. A. Fernandes, and M. J. Ramos,“Protein-ligand docking: current status and future challenges,” Proteins: Structure, Function, and Bioinformatics, vol. 65, no. 1, pp. 15–26, 2006.
14. M. Karplus and J. A. McCammon, “Molecular dynamics simulations of biomolecules,” Nature Structural Biology, vol. 9, no. 9, pp. 646–652, 2002.
15. J. C. Phillips, G. Zheng, S. Kumar, and L. V. Kalé, “NAMD: Biomolecular simulation on thousands of processors,” in ACM/IEEE SC 2002 Conference (SC’02), p. 36, Baltimore, MD, USA, 2002.
16. J. A. Rackers, Z. Wang, C. Lu et al., “Tinker 8: software tools for molecular design,” Journal of Chemical Theory and Computation, vol. 14, no. 10, pp. 5273–5289, 2018.
17. W. Smith, C. W. Yong, and P. M. Rodger, “DL_POLY: application to molecular simulation,” Molecular Simulation, vol. 28, no. 5, pp. 385–471, 2002.
18. P. Prathipati, A. Dixit, and A. K. Saxena, “Computer-aided drug design: integration of structure-based and ligand-based approaches in drug design,” Current Computer-Aided Drug Design, vol. 3, no. 2, pp. 133–148, 2007.
19. D. Schaller, D. sribar, T. Noonan et al., “Next generation 3D pharmacophore modeling,” Wiley Interdisciplinary Reviews: Computational Molecular Science, vol. 10, no. 4, article e1468, 2020.
20. J. H. Van Drie, “Generation of three-dimensional pharmacophore models,” Wiley Interdisciplinary Reviews: Computational Molecular Science, vol. 3, no. 5, pp. 449–464, 2013.
21. C. C. Melo-Filho, R. C. Braga, and C. H. Andrade, “3D-QSAR approaches in drug design: perspectives to generate reliable CoMFA models,” Current Computer-Aided Drug Design, vol. 10, no. 2, pp. 148–159, 2014.
22. A. Vuorinen and D. Schuster, “Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling,” Methods, vol. 71, pp. 113–134, 2015.
23. T. Klabunde, C. Giegerich, and A. Evers, “Sequence-derived three-dimensional pharmacophore models for G-proteincoupled receptors and their application in virtual screening,” Journal of Medicinal Chemistry, vol. 52, no. 9, pp. 2923–2932, 2009.
Research & Reviews: A Journal of Pharmaceutical Science
Volume | 15 |
Issue | 02 |
Received | May 10, 2024 |
Accepted | May 15, 2024 |
Published | July 19, 2024 |